Cross-intolerance with bosutinib after prior tyrosine kinase inhibitors for Philadelphia chromosome-positive leukemia: long-term analysis of a phase I/II study.

MLA

Cortes, Jorge E., et al. “Cross-Intolerance with Bosutinib after Prior Tyrosine Kinase Inhibitors for Philadelphia Chromosome-Positive Leukemia: Long-Term Analysis of a Phase I/II Study.” Haematologica, vol. 108, no. 12, Dec. 2023, pp. 3454–59. EBSCOhost, https://doi.org/10.3324/haematol.2022.281944.

APA

Cortes, J. E., Lipton, J. H., Kota, V., Castagnetti, F., Assouline, S., Brümmendorf, T. H., Leip, E., Viqueira, A., & Gambacorti-Passerini, C. (2023). Cross-intolerance with bosutinib after prior tyrosine kinase inhibitors for Philadelphia chromosome-positive leukemia: long-term analysis of a phase I/II study. Haematologica, 108(12), 3454–3459. https://doi.org/10.3324/haematol.2022.281944

Chicago

Cortes, Jorge E, Jeff H Lipton, Vamsi Kota, Fausto Castagnetti, Sarit Assouline, Tim H Brümmendorf, Eric Leip, Andrea Viqueira, and Carlo Gambacorti-Passerini. 2023. “Cross-Intolerance with Bosutinib after Prior Tyrosine Kinase Inhibitors for Philadelphia Chromosome-Positive Leukemia: Long-Term Analysis of a Phase I/II Study.” Haematologica 108 (12): 3454–59. doi:10.3324/haematol.2022.281944.